Affinage

SOX7

Transcription factor SOX-7 · UniProt Q9BT81

Length
388 aa
Mass
42.2 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SOX7 is an HMG-box transcription factor that orchestrates vascular, cardiac, hematopoietic, and endodermal cell-fate decisions through both sequence-specific DNA binding and protein-protein interactions (PMID:15220343, PMID:18094332, PMID:27802172). Through its HMG box it binds SOX consensus sites in target enhancers and promoters to activate transcription of laminin alpha1 in parietal endoderm (PMID:15220343), Fgf-3 (where it competes with GATA-4) (PMID:15082719), VE-cadherin in haemogenic and outflow-tract endothelium (PMID:22492353, PMID:33720353), and Wnt4/Bmp2 in the atrioventricular canal (PMID:33846290), while repressing other targets including a VEGFC regulatory locus, DNMT3B, and the proteasome-subunit PSME enhancer (PMID:36715213, PMID:39227479, PMID:30488457). In vascular development SOX7 acts redundantly with SOX17 and SOX18 to specify arteriovenous identity, functioning upstream of Notch/Gridlock(Hey2) and EphrinB2, with loss producing arteriovenous shunts and ectopic venous Flt4 expression (PMID:18094332, PMID:18377889, PMID:25834021, PMID:26630461); its own expression is driven by ETV2 and HIF during endothelial specification and hypoxic angiogenesis (PMID:24762086, PMID:32071080). SOX7 also restrains hematopoietic commitment from endothelium by directly inhibiting RUNX1 DNA binding and disrupting the RUNX1-CBFβ interaction (PMID:27802172), and sustains endothelial over hematopoietic identity in coronary and endocardial development (PMID:37551717). A second mode of action is direct binding to β-catenin, by which SOX7 depletes active β-catenin and competes with BCL9 and TCF4 to suppress Wnt/β-catenin transcription—a mechanism underlying its tumor-suppressive and pro-apoptotic roles, frequently lost through promoter hypermethylation in cancer (PMID:18819930, PMID:25940713, PMID:29271667, PMID:23295859). SOX7 cooperates with cardiac factors GATA4 and NKX2.5, and is induced by GATA4, to regulate cardiomyocyte and cardiovascular progenitor differentiation (PMID:29229250, PMID:31154937, PMID:35422912). Haploinsufficiency causes diaphragmatic hernia and homozygous loss causes cardiovascular failure in mice, and SOX7 mutations are found in congenital heart disease patients where they weaken transactivation of cardiac targets (PMID:22723016, PMID:33720353, PMID:35422912).

Mechanistic history

Synthesis pass · year-by-year structured walk · 22 steps
  1. 2001 Medium

    Established that SOX7 is a transcriptional activator that can antagonize Wnt/β-catenin signaling, defining its dual activator/repressor logic.

    Evidence Transactivation domain mapping and TCF/LEF reporter assays in cultured cells

    PMID:11691915

    Open questions at the time
    • No direct DNA targets identified
    • Mechanism of β-catenin antagonism not defined at this stage
  2. 2004 High

    Identified the first direct SOX7 DNA targets and an endodermal program, showing HMG-box-dependent activation of Lama1 and Fgf-3 and placement upstream of GATA-4/6.

    Evidence EMSA, luciferase reporter mutagenesis, siRNA knockdown and rescue in F9 embryonal carcinoma/embryoid body systems

    PMID:15082719 PMID:15220343 PMID:15542856

    Open questions at the time
    • Restricted to F9/embryoid-body context
    • Genome-wide target repertoire unknown
  3. 2005 High

    Demonstrated functional redundancy with SOX18 in cardiogenesis and showed β-catenin interaction is dispensable for this developmental activity, separating DNA-binding from protein-interaction modes.

    Evidence mRNA injection, morpholino knockdown, reciprocal rescue, and domain-swap experiments in Xenopus

    PMID:16193513

    Open questions at the time
    • Direct cardiac target genes not identified here
    • Relationship to mammalian heart development untested
  4. 2008 High

    Defined the redundant SoxF role in arteriovenous identity, placing sox7/sox18 upstream of Gridlock/Hey2 and arterial markers.

    Evidence Combinatorial morpholino knockdown with arteriovenous marker in situ hybridization in zebrafish

    PMID:18094332 PMID:18377889

    Open questions at the time
    • Direct vs indirect regulation of Hey2/EphrinB2 not resolved
    • Relative contribution of each SoxF gene unclear
  5. 2008 Medium

    Established the molecular basis of SOX7 Wnt antagonism in cancer—direct β-catenin binding and depletion—and linked promoter hypermethylation to its silencing as a tumor suppressor.

    Evidence Co-IP, luciferase reporter, bisulfite sequencing in prostate and colorectal cancer cells

    PMID:18819930

    Open questions at the time
    • Single-lab Co-IP
    • Whether DNA binding is required for tumor suppression not addressed here
  6. 2009 Medium

    Showed SOX7 restrains hematopoietic differentiation, maintaining multipotent self-renewing precursors during ES cell differentiation.

    Evidence Inducible Sox7 overexpression in ES cell differentiation with flow cytometry and colony assays

    PMID:19801444

    Open questions at the time
    • Direct transcriptional targets mediating the block not defined
    • Single gain-of-function system
  7. 2012 High

    Connected the endothelial/hematopoietic switch to a direct target, showing SOX7 binds and activates the VE-cadherin promoter and sustains endothelial identity in haemogenic endothelium; in vivo loss causes cardiovascular failure and diaphragmatic hernia.

    Evidence ChIP, luciferase reporter, ES cell gain-of-function; targeted Sox7 deletion mouse phenotyping

    PMID:22492353 PMID:22723016

    Open questions at the time
    • Mechanism linking endothelial maintenance to blood differentiation block not fully defined
    • Diaphragmatic hernia mechanism unresolved
  8. 2014 High

    Positioned SOX7 within the endothelial specification cascade as a direct ETV2 target mediating endothelial progenitor expansion.

    Evidence ChIP, reporter assay, shRNA knockdown and rescue in embryoid body differentiation

    PMID:24762086

    Open questions at the time
    • Downstream SOX7 effectors in this context not enumerated
  9. 2015 High

    Refined the arteriovenous mechanism by placing Sox7 genetically upstream of Notch and establishing reciprocal SoxF cross-regulation and Wnt-dependent SoxF expression.

    Evidence Zebrafish sox7 mutant epistasis with NICD rescue; mouse retina combinatorial conditional KO with Wnt/VEGF pathway interactions

    PMID:25834021 PMID:26630461

    Open questions at the time
    • Direct Notch-pathway target promoters of SOX7 not identified here
    • How Wnt signaling controls SoxF transcription unresolved
  10. 2016 High

    Defined a key protein-interaction mechanism in hematopoiesis: SOX7 directly inhibits RUNX1 by blocking its DNA binding and disrupting the RUNX1-CBFβ complex.

    Evidence Reciprocal Co-IP, single-cell expression, reporter assays in haemogenic endothelium

    PMID:27802172

    Open questions at the time
    • Structural basis of the SOX7-RUNX1 interaction unknown
    • In vivo requirement for this interaction not isolated
  11. 2016 High

    Detailed the β-catenin antagonism mechanism across tumor types—competition with BCL9 and binding to β-catenin/TCF4—and validated its requirement via domain deletion in AML.

    Evidence Co-IP, domain deletion functional assays, reporter assays, xenotransplantation in leukemia, endometrial, and hepatocellular cancer cells

    PMID:23295859 PMID:25940713 PMID:27058905 PMID:29271667

    Open questions at the time
    • Most evidence from single-lab Co-IP per context
    • Relative contribution of DNA binding vs β-catenin sequestration not quantified
  12. 2016 High

    Revealed context-dependent pro-tumor vascular functions, with SOX7 driving VEGFR2 and pericyte IL-33 to promote vascular abnormality and metastasis, contrasting its tumor-suppressor role.

    Evidence Conditional endothelial Sox7 deletion and xenograft gain/loss-of-function with pathway inhibition

    PMID:27150562 PMID:29444818

    Open questions at the time
    • Reconciliation of pro- vs anti-tumor roles by tissue context incomplete
    • Direct vs indirect VEGFR2 regulation not fully shown
  13. 2017 High

    Expanded the direct cardiac target set and cofactor network—SOX7 binds Wnt4/Bmp2 promoters to drive EndMT, cooperates with GATA4 and NKX2.5, and is itself induced by GATA4.

    Evidence Conditional KO mice, ChIP, protein rescue, ChIP-Seq/ATAC-Seq, Co-IP, cross-species knockdown/rescue, patient-variant reporter assays

    PMID:29229250 PMID:31154937 PMID:33846290 PMID:35422912

    Open questions at the time
    • Precise cooperativity mechanism with NKX2.5 not structurally defined
    • Genome-wide direct vs indirect targets partially resolved
  14. 2017 High

    Showed SOX7 represses an additional direct target (PSME) via SOX-box sites and demonstrated its nuclear localization signal, not the β-catenin motif, is essential for this repression—dissociating repression from Wnt antagonism.

    Evidence ChIP, EMSA, reporter assays with domain-deletion mutants in cancer cell lines

    PMID:30488457

    Open questions at the time
    • Generalizability of NLS-dependent repression to other targets untested
  15. 2017 High

    Defined the tissue-specific in vivo requirement for SOX7 in vascular progenitors and confirmed it is dispensable in committed hematopoietic cells.

    Evidence FLK1-Cre and VAV-Cre conditional knockout mouse embryo phenotyping

    PMID:28577909

    Open questions at the time
    • Direct effectors of vascular organization defect not identified here
  16. 2018 Medium

    Broadened the target landscape and effector mechanism in cancer, identifying direct activated (SPRY1, SLIT2) and repressed (TRIB3, MTHFD2) targets and a pro-apoptotic pathway stabilizing BIM via MEK/ERK and the proteasome.

    Evidence ChIP and microarray profiling in breast cancer; pharmacological pathway dissection of P38/MEK-ERK-BIM

    PMID:29757932 PMID:31332289

    Open questions at the time
    • Single-lab ChIP per target
    • Direct vs indirect control of BIM stability not fully resolved
  17. 2018 High

    Extended SOX7 function beyond vasculature to skeletal muscle, where it maintains satellite cells and supports myoblast fusion and regeneration.

    Evidence PAX3-Cre conditional KO mice, shRNA knockdown in primary myoblasts, in vivo injury model

    PMID:28943254

    Open questions at the time
    • Transcriptional targets in muscle stem cells not identified
  18. 2019 Medium

    Linked SOX7 to neuronal apoptosis and antibody-mediated endothelial activation, expanding its β-catenin and Notch (Jagged1) regulatory roles.

    Evidence Co-IP and apoptosis assays in hippocampal neurons; shRNA and Jagged1 rescue in endothelial transplant models

    PMID:25847511 PMID:30639059

    Open questions at the time
    • Single-lab studies
    • Direct vs indirect Jagged1/Notch regulation not established
  19. 2020 Medium

    Positioned SOX7 as an early HIF-dependent effector of hypoxia-driven angiogenesis in human endothelial cells.

    Evidence RNA-Seq, siRNA depletion, angiogenesis assays, HIF1A/EPAS1 depletion in primary human ECs

    PMID:32071080

    Open questions at the time
    • Direct HIF binding to SOX7 locus not shown
    • Single lab
  20. 2021 High

    Tied SOX7 directly to human congenital heart disease by showing patient mutations weaken VE-cadherin transactivation and impair EndMT during outflow-tract development.

    Evidence EMSA, luciferase, collagen-gel EndMT assay, patient variant functional analysis

    PMID:33720353

    Open questions at the time
    • Causality of patient variants in vivo not formally established
  21. 2023 High

    Established SOX7 as a non-cell-autonomous repressor of lymphatic patterning via direct VEGFC repression and a SOX7-HEY1 interaction, and as a maintainer of cardiac endothelial identity preventing endothelial-to-hematopoietic transdifferentiation.

    Evidence Endothelial conditional KO mice, regulatory-region binding assays, Co-IP for SOX7-HEY1, single-nuclei transcriptomics and fate mapping

    PMID:36715213 PMID:37551717

    Open questions at the time
    • Whether HEY1 recruitment to Vegfc regulatory regions is direct not fully proven
    • Mechanism of endothelial-to-hematopoietic transdifferentiation upon Sox7 loss incomplete
  22. 2024 Medium

    Added an epigenetic effector arm, showing SOX7 represses DNMT3B to lower CYGB promoter methylation and suppress bladder cancer, and attenuates liver fibrosis through β-catenin and TGF-β/Smad pathways.

    Evidence ChIP, bisulfite sequencing, in vivo tumor models; AAV8-SOX7 overexpression in CCl4 fibrosis model

    PMID:39126242 PMID:39227479

    Open questions at the time
    • Single-lab findings
    • Direct vs indirect Smad regulation not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the relative use of direct DNA binding versus β-catenin/RUNX1/HEY1 protein-interaction modes is selected across tissues, and what determines SOX7's context-dependent switch between tumor-suppressive and pro-angiogenic/pro-metastatic roles, remains unresolved.
  • No structural model of SOX7 cofactor complexes
  • Determinants of activator vs repressor output at individual loci unknown
  • Integrated logic across vascular, cardiac, hematopoietic, and cancer contexts not unified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 9 GO:0140110 transcription regulator activity 8 GO:0098772 molecular function regulator activity 5
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-1266738 Developmental Biology 8 R-HSA-1643685 Disease 6 R-HSA-74160 Gene expression (Transcription) 6 R-HSA-162582 Signal Transduction 5
Partners
BCL9CBFBCTNNB1GATA4HEY1NKX2.5RUNX1TCF4

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 SOX7 protein contains a functional transactivation domain in its C-terminus and is able to significantly reduce Wnt/beta-catenin-stimulated transcription in cell-based reporter assays. Transactivation domain mapping; TCF/LEF reporter assay Nucleic acids research Medium 11691915
2004 SOX7 and SOX17 bind specifically to two SOX-binding sites within the laminin alpha1 (Lama1) parietal endoderm-specific enhancer and trans-activate Lama1 transcription in F9 cells; this activation is HMG-box-dependent and synergistic with Sp1/Sp3 and NF-Y binding sites upstream. EMSA, luciferase reporter assay, mutational analysis, Northern blot The Journal of biological chemistry High 15220343
2004 SOX7 competes with GATA-4 for occupancy of the PS4A element in the Fgf-3 promoter and acts as a potent activator of Fgf-3 transcription; RNAi knockdown of Sox7 in GATA-4-deficient embryoid bodies virtually abolishes Fgf-3 expression. Luciferase reporter assay, EMSA, siRNA knockdown, in situ hybridization The Journal of biological chemistry High 15082719
2004 In F9 embryonal carcinoma cells, Sox7 acts upstream of Gata-4 and Gata-6 to regulate parietal endoderm differentiation; siRNA silencing of Sox7 blocks induction of Gata-4 and Gata-6 by retinoic acid/cAMP, while overexpression of Gata-4 or Gata-6 in Sox7-silenced cells restores differentiation. siRNA knockdown, overexpression, morphological analysis, Western blot, RT-PCR Molecular and cellular biology High 15542856
2005 In Xenopus, SOX7 and SOX18 function redundantly to induce cardiogenesis through Xnr2 (nodal) signaling; SOX7 RNA rescues the SOX18 morpholino phenotype and vice versa. Versions of SOX7 with the C-terminal beta-catenin interaction domain replaced by a transcriptional activator still induce cardiogenesis, indicating beta-catenin interaction is dispensable for this activity. mRNA injection, morpholino knockdown, animal cap explant assay, marker gene expression Developmental dynamics High 16193513
2007 In zebrafish, sox7 and sox18 play redundant but collectively essential roles in establishing arteriovenous identity; simultaneous morpholino knockdown of both genes causes arteriovenous fusions with failure of venous endothelial cell differentiation while endothelial specification is maintained. Morpholino knockdown, transgenic line imaging, in situ hybridization with arteriovenous markers Blood High 18094332
2008 Zebrafish Sox7 and Sox18 control arterial-venous identity by regulating Gridlock (Hey2) expression; double morphants display ectopic venous marker Flt4 in the dorsal aorta and loss of artery-specific markers EphrinB2a and Gridlock. Morpholino knockdown, in situ hybridization, gene expression analysis Developmental biology High 18377889
2008 SOX7 protein physically interacts with beta-catenin and suppresses beta-catenin-mediated transcription by depleting active beta-catenin; promoter hypermethylation silences SOX7 in prostate and colorectal cancers. Co-immunoprecipitation, luciferase reporter assay, bisulfite sequencing, ectopic expression Molecular cancer research Medium 18819930
2009 SOX7 and SOX17 can functionally substitute for SOX18 during lymphatic development in a strain-specific compensatory mechanism; they are activated specifically in the absence of SOX18 function in permissive strains. Genetic mouse model, conditional deletion, in vitro and in vivo functional substitution assays Development (Cambridge, England) High 19515696
2009 Sustained Sox7 expression in the earliest committed hematopoietic precursors (during ES cell differentiation) promotes maintenance of multipotent self-renewing status and blocks differentiation; removal of the Sox7 block leads to efficient erythroid and myeloid differentiation. Inducible Sox7 overexpression in ES cell differentiation system, flow cytometry, colony assays Blood Medium 19801444
2012 SOX7 binds and activates the VE-cadherin promoter in haemogenic endothelium; enforced SOX7 expression in haemangioblast-derived blast colonies blocks blood cell differentiation and sustains endothelial marker expression. Chromatin immunoprecipitation, luciferase reporter assay, ES cell differentiation gain-of-function Development (Cambridge, England) High 22492353
2012 Haploinsufficiency of Sox7 in mice causes anterior retrosternal diaphragmatic hernias; homozygous Sox7 null embryos die with cardiovascular failure. SOX7 is expressed in vascular endothelial cells of the developing diaphragm. Targeted gene deletion (Sox7 exon 2 deletion), immunohistochemistry, mouse phenotyping Human molecular genetics High 22723016
2014 ETV2 directly binds to ETV2 binding elements in the Sox7 upstream regulatory region and activates Sox7 transcription; Sox7 overexpression mimics ETV2 in promoting endothelial progenitor expansion, and Sox7 knockdown blocks ETV2-induced endothelial progenitor formation and angiogenic sprouting. ChIP, luciferase reporter assay, shRNA knockdown, embryoid body differentiation assay Stem cells and development High 24762086
2015 In zebrafish, sox7 mutants display arteriovenous shunt formation at specific arterial sites due to ectopic flt4 expression; genetic interaction experiments place Sox7 upstream of Notch (overexpression of Notch intracellular domain rescues sox7 mutant phenotype), and Sox7 interacts genetically with hey2 and efnb2 in arterial specification. Zebrafish sox7 mutant generation, in vivo imaging, in situ hybridization, genetic epistasis (NICD overexpression rescue), combinatorial mutant analysis Development (Cambridge, England) High 25834021
2015 In the mouse retina, Sox7 and Sox17 reciprocally regulate each other's expression; combined deletion of Sox7, Sox17, and Sox18 causes loss of arterial identity (loss of radial arteries/veins, dense capillary plexus), while a single Sox17 allele largely restores arterial identity. SoxF gene expression is reduced by loss of Norrin/Frizzled4-mediated Wnt signaling but not by VEGF signaling. Conditional vascular endothelial-specific gene deletion, retinal whole-mount imaging, molecular marker analysis, genetic interaction with Wnt and VEGF pathway mutants PloS one High 26630461
2016 SOX7 directly interacts with RUNX1 and inhibits its transcriptional activity; SOX7 hinders RUNX1 DNA binding and also disrupts the interaction between RUNX1 and its co-factor CBFβ in haemogenic endothelium. Co-immunoprecipitation, protein-protein interaction assays, single-cell expression profiling, immunofluorescence, functional reporter assays Development (Cambridge, England) High 27802172
2016 PDGF-BB activates SOX7 transcription factor in pericytes, which in turn drives IL-33 expression (the highest upregulated gene); IL-33 promotes metastasis through recruitment of tumour-associated macrophages via the ST2 receptor. Gain- and loss-of-function experiments in xenograft mouse models, pharmacological and genetic inhibition of IL-33-ST2, gene expression analysis Nature communications Medium 27150562
2016 In tumor endothelial cells of high-grade glioma, Sox7 promotes VEGFR2 expression and vascular abnormality; Sox7 deletion suppresses VEGFR2 expression and normalizes vessels, while Sox17 deletion exacerbates this by up-regulating Sox7. Conditional endothelial Sox7 deletion, Sox17 deletion, anti-VEGFR2 antibody treatment, tumor growth assays, gene expression analysis The Journal of experimental medicine High 29444818
2016 SOX7 inhibits Wnt/beta-catenin transcriptional activity in acute myeloid leukemia cells through direct protein binding to beta-catenin; deletion of the beta-catenin binding site of SOX7 significantly reduces its anti-leukemia effects. Co-immunoprecipitation, domain deletion mutant functional assay, xenogeneic transplantation, overexpression in leukemia cell lines and primary AML cells Blood High 25940713
2016 In endometrial cancer cells, Sox7 physically interacts with both wild-type and mutant beta-catenin as well as TCF4, and co-localizes with them in the nucleus; Sox7 inhibits TCF/LEF-1-dependent Wnt transcription and suppresses Wnt targets Cyclin D1 and c-Myc. Co-immunoprecipitation, immunofluorescence co-localization, luciferase reporter assay, Western blot Oncotarget Medium 23295859
2017 SOX7 suppresses Wnt signaling by competing with BCL9 to bind beta-catenin, thereby disrupting the beta-catenin/BCL9 interaction required for oncogenic transcription. Co-immunoprecipitation, SuperTOPFLASH reporter assay DNA and cell biology Medium 29271667
2017 Sox7 binds directly to the promoters of Wnt4 and Bmp2 in the atrioventricular canal; Sox7 deficiency in mice reduces Bmp2 expression in AV canal myocardium and Wnt4 in endocardium, impairing endothelial-to-mesenchymal transition (EndMT) required for atrioventricular cushion development. WNT4 or BMP2 protein partially rescues impaired EndMT caused by Sox7 deficiency. Conditional Sox7 knockout mice, ChIP (direct binding), transcriptome analysis, rescue experiments with recombinant WNT4/BMP2 protein Cell death & disease High 33846290
2017 GATA4 directly and specifically induces Sox7 (and Sox18) expression during cardiomyogenesis; Gata4 knockdown reduces Sox7/Sox18 expression and the cardiomyocyte differentiation defect can be partially restored by reinstating Sox7 or Sox18. Genome-wide transcriptomics in Xenopus and mouse ESCs, morpholino/shRNA knockdown, mRNA rescue, RT-PCR Developmental biology High 29229250
2017 SOX7 directly binds to the PSMA enhancer (PSME) at SOX box sites #2 and #4 and suppresses PSME-mediated transcription; the nuclear localization signal (NLS) region of SOX7, but not its beta-catenin interacting motif, is essential for this suppressive activity. ChIP, EMSA, luciferase reporter assay, domain deletion mutants, stable expression in cancer cell lines The Prostate High 30488457
2017 SOX7 directly binds to the HBV core promoter (HBVCP) and competitively displaces hepatocyte nuclear factor 4α to inhibit HBVCP transcription; stapled SOX7 HMG-box peptide mimetics recapitulate this inhibition in HBV-infected primary human hepatocytes. EMSA, luciferase reporter assay, pgRNA/HBcAg/cccDNA measurement, stapled peptide experiments in primary hepatocytes Journal of hepatology High 28887167
2018 SOX7 induces cellular apoptosis through upregulation of P38 and apoptotic signaling pathway genes, and prevents proteasome-mediated degradation of pro-apoptotic protein BIM. Proteasome inhibitors or MEK/ERK inhibitors attenuate SOX7-promoted BIM degradation. Gene expression analysis, pharmacological inhibition (MG132, bortezomib, U0126), Western blot, loss-of-function experiments Oncogene Medium 31332289
2018 SOX7 chromatin immunoprecipitation identifies SPRY1 and SLIT2 as direct SOX7-activated target genes, and TRIB3 and MTHFD2 as SOX7-repressed targets in breast cancer cells; these contribute to SOX7-mediated tumor suppression. Microarray gene expression profiling, ChIP assay, quantitative PCR validation, correlation with clinical dataset International journal of molecular sciences Medium 29757932
2019 SOX7 directly regulates cardiovascular progenitor cell fate by interfering with GATA4 transcriptional activity; protein-protein interaction between SOX7 and GATA4 was demonstrated, and Sox7 modulates WNT and BMP signaling during cardiovascular differentiation. ChIP-Seq and ATAC-Seq defined genome-wide Sox7 target genes in cardiac and endothelial progenitors. ChIP-Seq, ATAC-Seq, transcriptomics, Co-IP (protein-protein interaction), doxycycline-inducible ES cell system Stem cells and development High 31154937
2019 In hippocampal neurons, SOX7 overexpression promotes apoptosis by interacting with beta-catenin and suppressing its transcriptional activity (not through protein degradation); beta-catenin inhibition mediates the pro-apoptotic effect of SOX7 in potassium deprivation-induced neuronal apoptosis. Co-immunoprecipitation, overexpression/knockdown, apoptosis assays, reporter assay The European journal of neuroscience Medium 25847511
2019 Sox7 plays a role in antibody-dependent endothelial cell activation via the Jagged1-Notch1 pathway; Sox7 knockdown reduces HLA antibody-induced expression of adhesion molecules and cytokines, and Jagged1 overexpression rescues the inhibitory effects of Sox7 knockdown. shRNA knockdown, overexpression, in vitro HKGEC model, in vivo kidney transplantation model, Western blot Experimental cell research Medium 30639059
2017 SOX7 is expressed in FLK1-expressing vascular progenitor cells and its deletion causes defective vascular organization from E8.5 onward; conditional deletion of Sox7 in FLK1+ cells leads to widespread vascular defects by E10.5, while VAV-specific Sox7 deletion does not affect haematopoiesis. Conditional knockout mice (FLK1-Cre and VAV-Cre), embryo phenotyping, immunostaining, endothelial marker analysis Mechanisms of development High 28577909
2020 SOX7 depletion in human endothelial cells impairs hypoxia-induced angiogenesis; SOX7 expression is rapidly and transiently induced during hypoxia through HIF-dependent mechanisms, and is an early regulator of the angiogenic transcriptional program. RNA-Seq, SOX7 siRNA depletion, functional angiogenesis assays, HIF1A/EPAS1 depletion for pathway positioning The Journal of biological chemistry Medium 32071080
2021 SOX7 directly up-regulates VE-cadherin by binding to its gene promoter in endothelial cells, thereby suppressing EndMT during outflow tract development. SOX7 mutations found in congenital heart disease patients weaken transactivation of the VE-cadherin promoter. Luciferase reporter assay, EMSA, collagen gel EndMT assay, overexpression experiments, patient variant functional analysis Clinical science High 33720353
2022 A truncating SOX7 variant (Gln104*) fails to transactivate its target genes GATA4 and BMP2, and also loses the ability to cooperatively transactivate with NKX2.5, establishing GATA4, BMP2, and cooperative NKX2.5 interaction as functionally important targets of SOX7 in cardiac development. Dual-luciferase reporter assay with wild-type and mutant SOX7, co-transfection with NKX2.5 American journal of translational research Medium 35422912
2023 SOX7 in blood vascular endothelial cells (BECs) directly represses VEGFC transcription by binding to distant regulatory regions of the Vegfc locus, and SOX7 directly binds HEY1, a Notch pathway repressor, suggesting recruitment of HEY1 at Vegfc regulatory regions. Endothelial-specific loss of SOX7 causes dysmorphic dermal lymphatic phenotype through non-cell-autonomous regulation of lymphatic patterning. Conditional endothelial Sox7 knockout mouse, identification of Vegfc regulatory regions, ChIP/binding assays, Co-IP for SOX7-HEY1 interaction The EMBO journal High 36715213
2023 Endothelial-specific loss of Sox7 in mice causes ventricular non-compaction cardiomyopathy with abnormal coronary artery formation; Sox7 maintains cardiac endothelial identity by regulating the Notch pathway and connexins 37 and 40 for coronary arterial specification. Sox7-null endothelial cells transdifferentiate into hematopoietic lineages; single-nuclei transcriptomics identifies depletion of Sox9/Gpc3-positive endocardial progenitors. Endothelial-specific conditional KO, single-nuclei transcriptomics, fate mapping, histology EMBO reports High 37551717
2024 SOX7 binds to the promoter of DNMT3B and transcriptionally inhibits DNMT3B expression, resulting in reduced methylation of the CYGB promoter and inhibiting bladder cancer progression. ChIP assay (SOX7 binding to DNMT3B promoter), bisulfite sequencing (CYGB methylation), overexpression/knockdown, in vivo tumor models Molecular biomedicine Medium 39227479
2016 In hepatocellular carcinoma cells, Sox7 physically binds with beta-catenin and TCF4 in the nucleus and inhibits the activity of Wnt/beta-catenin signaling pathway; miR-452 promotes stem-like characteristics by directly targeting Sox7. Co-immunoprecipitation, luciferase reporter assay, in vitro and in vivo stem-like cell assays Oncotarget Medium 27058905
2018 Sox7 knockdown in primary myoblasts causes impaired myoblast fusion and increased sensitivity to apoptosis; conditional Sox7 knockout in PAX3+ cells in vivo reduces the satellite cell population from birth, reduces myofiber caliber, and impairs muscle regeneration after injury. Conditional knockout mouse (PAX3-Cre), shRNA knockdown in primary myoblasts, ES cell differentiation, in vivo injury model Stem cell reports High 28943254
2024 SOX7 attenuates hepatic stellate cell (HSC) activation and liver fibrosis by decreasing beta-catenin expression and reducing TGF-β1-induced phosphorylation of Smad2 and Smad3; AAV8-SOX7 overexpression in mice ameliorates CCl4-induced liver fibrosis in vivo. AAV8-mediated overexpression in mouse fibrosis model, siRNA knockdown, Western blot, in vivo CCl4 model FASEB journal Medium 39126242
2011 SOX7 is upregulated by aspirin in colorectal cancer cells via the p38MAPK pathway; AP1 transcription factors c-Jun and c-Fos upregulate SOX7 promoter activity, and SOX7 mediates aspirin-induced growth inhibition. Luciferase reporter assay, p38MAPK inhibition (SB203580), RT-PCR, Western blot, MTT assay World journal of gastroenterology Medium 22171135

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Sox18 and Sox7 play redundant roles in vascular development. Blood 165 18094332
2016 The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages. Nature communications 157 27150562
2001 SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling. Nucleic acids research 147 11691915
2017 LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. OncoTargets and therapy 106 29123412
2008 Zebrafish Sox7 and Sox18 function together to control arterial-venous identity. Developmental biology 105 18377889
2009 Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice. Development (Cambridge, England) 84 19515696
2015 Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina. PloS one 81 26630461
2008 Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Molecular cancer research : MCR 81 18819930
2012 Mouse model reveals the role of SOX7 in the development of congenital diaphragmatic hernia associated with recurrent deletions of 8p23.1. Human molecular genetics 73 22723016
2005 SOX7 and SOX18 are essential for cardiogenesis in Xenopus. Developmental dynamics : an official publication of the American Association of Anatomists 73 16193513
2004 Sox7 plays crucial roles in parietal endoderm differentiation in F9 embryonal carcinoma cells through regulating Gata-4 and Gata-6 expression. Molecular and cellular biology 70 15542856
2012 SOX7 regulates the expression of VE-cadherin in the haemogenic endothelium at the onset of haematopoietic development. Development (Cambridge, England) 69 22492353
2008 SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer letters 69 19108950
2004 SOX7 and SOX17 regulate the parietal endoderm-specific enhancer activity of mouse laminin alpha1 gene. The Journal of biological chemistry 68 15220343
2002 Expression of human SOX7 in normal tissues and tumors. International journal of molecular medicine 68 11891528
2018 miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7. Journal of cellular biochemistry 67 29231262
2016 MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/β-catenin signaling pathway. Oncotarget 65 27058905
2012 Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget 65 23295859
2013 SOX7 is down-regulated in lung cancer. Journal of experimental & clinical cancer research : CR 63 23557216
2009 Sox7-sustained expression alters the balance between proliferation and differentiation of hematopoietic progenitors at the onset of blood specification. Blood 61 19801444
2014 Mir-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PloS one 60 24558429
2014 MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 60 25407488
2017 MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. Journal of cellular and molecular medicine 57 28266181
2013 SOX7: from a developmental regulator to an emerging tumor suppressor. Histology and histopathology 55 24288056
2013 The regulation of SOX7 and its tumor suppressive role in breast cancer. The American journal of pathology 54 24012678
2015 Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood 50 25940713
2004 SOX7 and GATA-4 are competitive activators of Fgf-3 transcription. The Journal of biological chemistry 50 15082719
2016 miR-935 Promotes Liver Cancer Cell Proliferation and Migration by Targeting SOX7. Oncology research 48 27697092
2014 miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 48 25073511
2015 Sox7 controls arterial specification in conjunction with hey2 and efnb2 function. Development (Cambridge, England) 44 25834021
2019 LncRNA FTX inhibits hippocampal neuron apoptosis by regulating miR-21-5p/SOX7 axis in a rat model of temporal lobe epilepsy. Biochemical and biophysical research communications 43 30871773
2019 SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene 43 31332289
2019 Long noncoding RNA XIST participates hypoxia-induced angiogenesis in human brain microvascular endothelial cells through regulating miR-485/SOX7 axis. American journal of translational research 43 31737200
2018 Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality. The Journal of experimental medicine 41 29444818
2014 Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway. Journal of ovarian research 41 25297608
2009 SOX15 and SOX7 differentially regulate the myogenic program in P19 cells. Stem cells (Dayton, Ohio) 40 19489079
2016 miR-935 promotes gastric cancer cell proliferation by targeting SOX7. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 36 27044823
2016 SOX7 is associated with the suppression of human glioma by HMG-box dependent regulation of Wnt/β-catenin signaling. Cancer letters 35 26944317
2016 MiR-595 targeting regulation of SOX7 expression promoted cell proliferation of human glioblastoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 33 27133048
2018 MicroRNA-494-3p Promotes Cell Growth, Migration, and Invasion of Nasopharyngeal Carcinoma by Targeting Sox7. Technology in cancer research & treatment 32 30381030
2016 Interplay between SOX7 and RUNX1 regulates hemogenic endothelial fate in the yolk sac. Development (Cambridge, England) 32 27802172
2015 Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clinical and experimental medicine 31 26515813
2016 SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer. Scientific reports 29 27188720
2014 The suppressive role of SOX7 in hepatocarcinogenesis. PloS one 28 24816720
2018 Overexpression of microRNA-34a Attenuates Proliferation and Induces Apoptosis in Pituitary Adenoma Cells via SOX7. Molecular therapy oncolytics 27 30109259
2017 SOX7 expression is critically required in FLK1-expressing cells for vasculogenesis and angiogenesis during mouse embryonic development. Mechanisms of development 26 28577909
2014 Sox7 is regulated by ETV2 during cardiovascular development. Stem cells and development 26 24762086
2020 ACTA2-AS1 suppresses lung adenocarcinoma progression via sequestering miR-378a-3p and miR-4428 to elevate SOX7 expression. Cell biology international 25 32808728
2017 MicroRNA-616 promotes the growth and metastasis of non-small cell lung cancer by targeting SOX7. Oncology reports 25 28765960
2017 MiR-616 promotes proliferation and inhibits apoptosis in glioma cells by suppressing expression of SOX7 via the Wnt signaling pathway. European review for medical and pharmacological sciences 25 29271996
2014 Sox7 in vascular development: review, insights and potential mechanisms. The International journal of developmental biology 25 24860989
2008 Lineage specification of Flk-1+ progenitors is associated with divergent Sox7 expression in cardiopoiesis. Differentiation; research in biological diversity 24 19272523
2004 Embryonic expression of Xenopus laevis SOX7. Gene expression patterns : GEP 24 14678825
2018 SOX7 Target Genes and Their Contribution to Its Tumor Suppressive Function. International journal of molecular sciences 23 29757932
2020 Long noncoding RNA HAND2-AS1 restrains proliferation and metastasis of breast cancer cells through sponging miR-1275 and promoting SOX7. Cancer biomarkers : section A of Disease markers 21 31683462
2017 SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction. DNA and cell biology 20 29271667
2021 CircUBQLN1 Promotes Proliferation but Inhibits Apoptosis and Oxidative Stress of Hippocampal Neurons in Epilepsy via the miR-155-Mediated SOX7 Upregulation. Journal of molecular neuroscience : MN 19 33835399
2017 Genome-wide transcriptomics analysis identifies sox7 and sox18 as specifically regulated by gata4 in cardiomyogenesis. Developmental biology 19 29229250
2016 SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24. Open medicine (Warsaw, Poland) 19 28352781
2020 Long non-coding RNA NBAT1 inhibits the progression of glioma through the miR-21/SOX7 axis. Oncology letters 18 32782620
2018 Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18 29957056
2020 Comprehensive transcriptomic profiling reveals SOX7 as an early regulator of angiogenesis in hypoxic human endothelial cells. The Journal of biological chemistry 17 32071080
2018 Knockdown of miR‑935 increases paclitaxel sensitivity via regulation of SOX7 in non‑small‑cell lung cancer. Molecular medicine reports 17 30066948
2011 SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. World journal of gastroenterology 17 22171135
2017 Long noncoding RNA AB073614 promotes the malignance of glioma by activating Wnt/β-catenin signaling through downregulating SOX7. Oncotarget 16 29029454
2019 Sox7 Regulates Lineage Decisions in Cardiovascular Progenitor Cells. Stem cells and development 15 31154937
2019 MiR-128/SOX7 alleviates myocardial ischemia injury by regulating IL-33/sST2 in acute myocardial infarction. Biological chemistry 14 30265647
2018 A novel role for sox7 in Xenopus early primordial germ cell development: mining the PGC transcriptome. Development (Cambridge, England) 14 29158442
2022 The mechanism by which crocetin regulates the lncRNA NEAT1/miR-125b-5p/SOX7 molecular axis to inhibit high glucose-induced diabetic retinopathy. Experimental eye research 13 35718188
2019 MiRNA-616 aggravates the progression of bladder cancer by regulating cell proliferation, migration and apoptosis through downregulating SOX7. European review for medical and pharmacological sciences 13 31773697
2018 miR-184 promotes cell proliferation in tongue squamous cell carcinoma by targeting SOX7. Oncology letters 13 30008922
2015 SOX7 interferes with β-catenin activity to promote neuronal apoptosis. The European journal of neuroscience 13 25847511
2021 The transcription factor Sox7 modulates endocardiac cushion formation contributed to atrioventricular septal defect through Wnt4/Bmp2 signaling. Cell death & disease 12 33846290
2018 Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer. The Prostate 12 30488457
2013 A potential relationship among beta-defensins haplotype, SOX7 duplication and cardiac defects. PloS one 11 24009689
2023 The blood vasculature instructs lymphatic patterning in a SOX7-dependent manner. The EMBO journal 10 36715213
2022 miR-146a Inhibited Pancreatic Cancer Cell Proliferation by Targeting SOX7. Journal of healthcare engineering 10 35222878
2021 SOX7 suppresses endothelial-to-mesenchymal transitions by enhancing VE-cadherin expression during outflow tract development. Clinical science (London, England : 1979) 10 33720353
2020 SOX7 is involved in polyphyllin D-induced G0/G1 cell cycle arrest through down-regulation of cyclin D1. Acta pharmaceutica (Zagreb, Croatia) 10 31955140
2019 Novel role of sex-determining region Y-box 7 (SOX7) in tumor biology and cardiovascular developmental biology. Seminars in cancer biology 10 31473269
2019 Dll4 Blockade Promotes Angiogenesis in Nonhealing Wounds of Sox7-Deficient Mice. Advances in wound care 10 33095124
2022 SOX7 loss-of-function variation as a cause of familial congenital heart disease. American journal of translational research 9 35422912
2015 Sox7 is dispensable for primitive endoderm differentiation from mouse ES cells. BMC developmental biology 9 26475439
2022 LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis. Molecular biology reports 8 35332412
2017 Identification of Slug and SOX7 as transcriptional repressors binding to the hepatitis B virus core promoter. Journal of hepatology 8 28887167
2024 Alveolar type 2 cells marker gene SFTPC inhibits epithelial-to-mesenchymal transition by upregulating SOX7 and suppressing WNT/β-catenin pathway in non-small cell lung cancer. Frontiers in oncology 7 39346732
2017 SOX7 Is Required for Muscle Satellite Cell Development and Maintenance. Stem cell reports 7 28943254
2023 Sox7-positive endothelial progenitors establish coronary arteries and govern ventricular compaction. EMBO reports 6 37551717
2018 miR-452 promotes cell metastasis and the epithelial to mesenchymal by targeting SOX7 in clear-cell renal-cell carcinoma. Journal of cellular biochemistry 6 30506716
2016 SOX7-enforced expression promotes the expansion of adult blood progenitors and blocks B-cell development. Open biology 6 27411892
2024 SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis. Molecular biomedicine 5 39227479
2016 SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells. Oncotarget 5 29029405
2024 VEGF-dependent testicular vascularisation involves MEK1/2 signalling and the essential angiogenesis factors, SOX7 and SOX17. BMC biology 4 39354506
2023 Salvianolic acid A improves nerve regeneration and repairs nerve defects in rats with brain injury by downregulating miR-212-3p-mediated SOX7. The Kaohsiung journal of medical sciences 4 37987200
2022 SOX7 modulates the progression of hepatoblastoma through the regulation of Wnt/β-catenin signaling pathway. Journal of cancer research and therapeutics 4 35645102
2021 RETRACTED: MicroRNA-376b-5p targets SOX7 to alleviate ischemic brain injury in a mouse model through activating Wnt/β-catenin signaling pathway. Life sciences 4 33482187
2021 SOX7 blocks vasculogenic mimicry in oral squamous cell carcinoma. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 4 33733517
2019 Sox7 is involved in antibody-dependent endothelial cell activation and renal allograft injury via the Jagged1-Notch1 pathway. Experimental cell research 3 30639059
2016 [Aberrant methylation of the promoter regions of the SOX7 and p15INK4b genes and Wnt signaling pathway antagonists in patients with acute myeloid leukemias]. Terapevticheskii arkhiv 3 27459612
2024 System analysis based on weighted gene co-expression analysis identifies SOX7 as a novel regulator of hepatic stellate cell activation and liver fibrosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2 39126242

Missed literature

Know a paper Affinage missed for SOX7? Flag it for the maintainers and the community.

No submissions yet.